CX3CL1 and liver cancer: However, a study on the prognosis of patients with liver cancer showed that patients with high expression of CX3CL1 and its receptor had a better prognosis than those with low expression, with a significantly lower local recurrence rate and distant metastasis rate and longer disease-free survival and overall survival (15).